Vaccitech, 만성 HBV에 대한 임상1b/2a상 시험에서 긍정적인 초기 효능성 분석 결과 도출
December 07, 2021 10:30 ET
|
Vaccitech (UK) Limited
만성B형간염(CHB) 환자를 대상으로 한 3개월 간의 HBV002 임상연구 마친 27명의 환자들의 초기 데이터를 보면, 표면 항원(HBsAg) 수치가 눈에 띄는 변화를 나타냈으며, 이는 다른 종류의 부스트(VTP-300)와 저용량 nivolumab을 투여 받은 그룹에서 두드러져 HBV002 임상연구는 현재 4개 환자 그룹 모집 중으로...
Vaccitech reports promising interim efficacy analysis in Phase 1b/2a clinical study in chronic HBV
December 07, 2021 08:00 ET
|
Vaccitech (UK) Limited
Interim data from 27 patients, who had completed 3 months in the HBV002 study in chronic Hepatitis B (CHB) patients, demonstrated noted changes in surface antigen (HBsAg) levels, especially in the...
Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference
November 24, 2021 09:20 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech의 VTP-300, 건강한 지원자 및 만성B형간염 환자 모두가 보유한 모든 표적 HBV 항원에 대해 우수한 내약성 및 T세포 유도 능력 보였다는 초기 결과 발표
November 12, 2021 21:55 ET
|
Vaccitech (UK) Limited
HBV001 및 HBV002 연구의 초기 데이터, 만성B형간염(CHB) 환자의 경우 이종 프라임-부스트 벡터 조합인 ChAdOx1-HBV + MVA-HBV (VTP-300)가 B형간염 바이러스 항원 표적에 대해 강력한 T세포 면역 반응 유도 ChAdOx-1-HBV (HBV001) 단독으로 쓰일 경우 건강한 지원자 및 CHB 환자에 대한 내약성 뛰어나;...
在中期分析中，Vaccitech的VTP-300对健康志愿者和慢性HBV感染患者中都具有良好耐受性，并可诱发T细胞对抗所有靶向HBV抗原
November 12, 2021 21:55 ET
|
Vaccitech (UK) Limited
HBV001和HBV002这两项研究的中期数据表明，在慢性乙型肝炎（CHB）患者中，ChAdOx1-HBV + MVA-HBV（VTP-300）的异源初免-加强载体组合诱发T细胞积极对抗靶向乙型肝炎病毒抗原。 仅ChAdOx-1-HBV（HBV001）在健康志愿者和CHB患者中表现出良好的耐受性；VTP-300（HBV002）在CHB患者中表现出良好的耐受性。 ...
Vaccitech’s VTP-300 was Well-Tolerated and Induced T cells against all targeted HBV antigens in both Healthy Volunteers and Patients with Chronic HBV Infection in Interim Analyses
November 12, 2021 08:00 ET
|
Vaccitech (UK) Limited
Interim data from two studies, HBV001 and HBV002, showed that in chronic Hepatitis B (CHB) patients the heterologous prime-boost vector combination, ChAdOx1-HBV + MVA-HBV (VTP-300), induced robust T...
Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments
November 12, 2021 07:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) today announced its financial results for the third quarter, ended September 30, 2021, and provided an overview...
Vaccitech to Present at the Jefferies London Healthcare Conference
November 10, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, United Kingdom, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel...
Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus
November 04, 2021 04:00 ET
|
Vaccitech (UK) Limited
The Phase 1 clinical trial was conducted by The King Abdullah International Medical Research Centre (KAIMRC), in the Kingdom of Saudi Arabia (KSA), in partnership with the University of Oxford....
Vaccitech Announces Data Presentations at AASLD’s Liver Meeting® 2021
October 18, 2021 08:00 ET
|
Vaccitech (UK) Limited
OXFORD, U.K., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and...